Send to a Friend Share

Endo Pharma (ENDP) September volatility at 30, January at 35; shares near 32-month high

August 18, 2010 10:22 AM EDT
ENDP Hot Sheet
Overall Analyst Rating:
    BUY (= Flat)

EPS Growth %: -13.0%
Endo Pharmaceuticals (Nasdaq: ENDP) is recently up $1.70 to $27.84. ENDP announced on August 9th an agreement to acquire all outstanding shares of Penwest Pharmaceuticals (Nasdaq: PPCO) for $5.00 in cash per share. Jefferies has a Buy rating on ENDP. September option implied volatility is at 30, October is at 31, January is at 35; verses its six-month average of 30 according to Track Data. Paul Foster


Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In


Related Categories

Options

Related Entities

Jefferies & Co, Options

Add Your Comment





Follow StreetInsider.com On Twitter